These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 20124517)

  • 1. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
    Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
    Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
    Garg V; Chandorkar G; Yang Y; Adda N; McNair L; Alves K; Smith F; van Heeswijk RP
    Br J Clin Pharmacol; 2013 Feb; 75(2):431-9. PubMed ID: 22642697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.
    Liu Y; Zhou S; Wan Y; Wu A; Palmisano M
    Br J Clin Pharmacol; 2014 Nov; 78(5):1050-7. PubMed ID: 24962564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.
    Pithavala YK; Tortorici M; Toh M; Garrett M; Hee B; Kuruganti U; Ni G; Klamerus KJ
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):563-70. PubMed ID: 19603168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors.
    Cannady EA; Wang MD; Friedrich S; Rehmel JL; Yi P; Small DS; Zhang W; Suico JG
    Pharmacol Res Perspect; 2015 Oct; 3(5):e00179. PubMed ID: 26516590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and action of proteasome inhibitors in primary human hepatocytes.
    Lee CM; Kumar V; Riley RI; Morgan ET
    Drug Metab Dispos; 2010 Dec; 38(12):2166-72. PubMed ID: 20837660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.
    Tuloup V; France M; Garreau R; Bleyzac N; Bourguignon L; Tod M; Goutelle S
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0104321. PubMed ID: 34228545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Model for Predicting the Interindividual Variability of Drug-Drug Interactions.
    Tod M; Bourguignon L; Bleyzac N; Goutelle S
    AAPS J; 2017 Mar; 19(2):497-509. PubMed ID: 27924615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial.
    Spinelli T; Moresino C; Baumann S; Timmer W; Schultz A
    Springerplus; 2014; 3():389. PubMed ID: 25105088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole.
    Darpo B; Ferber G; Zhou M; Sumeray M; Sager P
    Ann Noninvasive Electrocardiol; 2013 Nov; 18(6):577-89. PubMed ID: 24118671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.
    Calcagnile S; Lanzarotti C; Rossi G; Henriksson A; Kammerer KP; Timmer W
    Support Care Cancer; 2013 Oct; 21(10):2879-87. PubMed ID: 23748441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
    Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
    Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
    Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lurasidone drug-drug interaction studies: a comprehensive review.
    Chiu YY; Ereshefsky L; Preskorn SH; Poola N; Loebel A
    Drug Metabol Drug Interact; 2014; 29(3):191-202. PubMed ID: 24825095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.
    Ramanathan S; Jin F; Sharma S; Kearney BP
    Clin Pharmacokinet; 2016 Jan; 55(1):33-45. PubMed ID: 26242379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
    Johnson BM; Adams LM; Zhang K; Gainer SD; Kirby LC; Blum RA; Apseloff G; Morrison RA; Schutz RA; Lebowitz PF
    J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
    Kirby LC; Johnson BM; Adams LM; Eberwein DJ; Zhang K; Murray SC; Lates CD; Blum RA; Morris SR
    J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.